A single low dose of dendritic cells modified with lentivirus containing a truncated neu gene can effectively suppress neu-overexpressing tumors.
BACKGROUND
Several types of viral-transduced HER2/neu-modified dendritic cells (DC(HER2/neu)) have been used for preventing and/or treating HER2/neu-overexpressing tumors. However, to date, lentivirus has not been used to generate HER2/neu-modified DCs.


METHODS
In the present study, we used recombinant lentivirus containing a truncated neu gene (rLVneu) to transduce murine bone marrow-derived dendritic cells and investigated their preventive and therapeutic effects on HER2/neu-overexpressing tumors.


RESULTS
The data obtained show that a single low dose of lentiviral-transduced DC(HER2/neu) could significantly elevate serum anti-neu antibody level, stimulate the proliferation of CD4 and CD8 T lymphocytes and interferon-gamma secretion, induce a long lasting preventive effect against HER2/neu-overexpressing tumors and significantly suppress the growth of established HER2/neu-overexpressing tumors.


CONCLUSIONS
The present study demonstrates that a single low dose of DCs modified with rLV containing a truncated neu oncogene can achieve a strong and long lasting effect on neu-overexpressing tumors, suggesting the possible clinical application of this strategy.
Institute of Human Reproduction and Stem Cell Engineering, Central South University, National Engineering and Research Center of Human Stem Cell, Changsha, China.
Gong-Bo
GB
Li
Guang-Xiu
GX
Lu
D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D018572:Disease-Free Survival; D007371:Interferon-gamma / Q000378:metabolism; D016086:Lentivirus / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D050505:Mutant Proteins / Q000235:genetics*; D009369:Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D010641:Phenotype; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013997:Time Factors; D014161:Transduction, Genetic; D014611:Vaccination
D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D007371:Interferon-gamma; D050505:Mutant Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases